Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi ...

The therapy is designed to silence both PCSK9 and APOC3 genes simultaneously.

RNAi combined with optimized delivery technology To specifically target the mold Aspergillus fumigatus, the researchers combined an RNAi approach with optimized delivery technology from nanomedicine.

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million ...

Parkinson’s disease is associated with the buildup of a particular brain protein that currently has no approved therapies addressing it. Novartis was among the companies pursuing this target, but its ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic ...